AnaptysBio (NASDAQ:ANAB) Given New $36.00 Price Target at JPMorgan Chase & Co.
AnaptysBio (NASDAQ:ANAB – Get Free Report) had its target price reduced by research analysts at JPMorgan Chase & Co. from $66 ...
Investing18d
AnaptysBio shares target cut, hold rating kept on trial failure
On Wednesday, Truist Securities adjusted its outlook on shares of AnaptysBio (NASDAQ:ANAB), reducing the stock's price target from $30.00 to $20.00, while maintaining a Hold rating on the shares. The ...
Nasdaq18d
Deep Dive Into AnaptysBio Stock: Analyst Perspectives (9 Ratings)
AnaptysBio (NASDAQ:ANAB) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ...
Seeking Alpha18d
AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout
I will address that right away. On December 11, 2024, AnaptysBio announced topline results of its Phase 2B trial for ANB032 for the treatment of atopic dermatitis. The trial failed, and as a ...
Investing18d
AnaptysBio shares target cut, hold rating kept on trial failure
On Wednesday, Truist Securities adjusted its outlook on shares of AnaptysBio (NASDAQ:ANAB), reducing the stock's price target from $30.00 to $20.00, while maintaining a Hold rating on the shares.